Graft-vs-Host Disease (GVHD)

Latest News


ASH 2024 Post Conference Perspectives: Chronic Graft-vs-Host Disease Management

Learn about emerging therapies such as axatilimab, and ibrutinib and rituximab combinations, and how they’re reshaping the treatment landscape for chronic graft-vs-host disease.

ASH 2024 Post Conference Perspectives: Chronic Graft-vs-Host Disease Management

Latest Videos


CME Content


More News

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo